Category: Cancer

Patient preferences for attributes of bispecific antibodies for relapse/refractory diffuse large B-cell lymphoma in the US

Jason Shafrin

That is the title of a paper published today in Future Oncology with co-authors Erin Mulvey, Kyi-Sin Than, Sanjana Muthukrishnan, Alex Mutebi, Anindit Chhibber, Anthony Wang, Abualbishr Alshreef, Diala Harb, Victor Gonzalez, Sarah Quinlan, Vardhaman Patel and Patrick Connor Johnson. The study was conducted in collaboration with the Lymphoma Research Foundation. The abstract is below:…

Imaging Utilization and Treatment Patterns of Brain Metastases in Patients with Non-Small Cell Lung Cancer

Jason Shafrin

That is the title of my most recent paper published in Clinical Lung Cancer with co-authors Mark Danese, Melissa Laurie, Beata Korytowsky, Shane Jordan, Debbie Ryan and Sukhmani K. Padda. The study abstract is below. ObjectiveThis study examined brain metastases among patients with metastatic non-small cell lung cancer (mNSCLC), characterizing prevalence, use of brain imaging,…

ISPOR 2025 Award Winners

Jason Shafrin

ISPOR recently released their award winners from their 2025 conference this May. Winners are listed below. I’m excited to announce that my podium presentation “Quantifying Treatment Value Using Alternative Health Benefit Metrics: A Case Study of Adjuvant Osimertinib for Elderly Patients with EGFR mutated NSCLC Following Resection” received an award for the Best General Podium…

Inequalities in CAR T-Cell Therapy Access for US Patients with Relapsed/Refractory DLBCL

Jason Shafrin

That is the title of my recent publication with co-authors Andrea Chung, Sachin Vadgama, Kristen Hurley, Miguel-Angel Perales, Leonard Clarkson Alsfeld, Sanjana Muthukrishnan and Anik R Patel, Gunjan L Shah, Richard T Maziarz. The abstract is below. CAR T-cell therapy has shown curative potential for patients with diffuse large B-cell lymphoma (DLBCL) and other malignancies,…

Can Recurrence-Free or Disease-Free Survival be used Surrogate Endpoints for Overall Survival in Esophageal Cancer?

Jason Shafrin

The answer appears to be ‘yes’ according a recent paper written by Uchechukwu Love Anyaduba, Oluwatosin Qawiyy Orababa, Zion Faye, Nazia Rashid, Gregory Reardon and myself. The abstract is below: BackgroundCancer trials increasingly use surrogate endpoints, but it is unclear how well recurrence-free survival (RFS) or disease-free survival (DFS) specifically predict overall survival (OS) in…

Out of Pocket Costs for Follow-Up Tests After Abnormal Screening Mammogram and Their Impact on Breast Cancer Survival

Jason Shafrin

Today, the American Cancer Society’s Cancer Action Network released a report titled “Out of Pocket Costs for Follow-Up Tests After Abnormal Screening Mammogram and Their Impact on Breast Cancer Survival.” The empirical analysis was conducted by myself and some colleagues at FTI Consulting (Shanshan Wang, Shurui Zhang, Citseko Staples Miller, and Sophia Mildred Setterberg). An…